Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

IVF booster offered in Canada but not US

Alison Motluk
CMAJ February 17, 2015 187 (3) E89-E90; DOI: https://doi.org/10.1503/cmaj.109-4975
Alison Motluk
Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A new fertility treatment that purports to help older women get pregnant by boosting the energy in their eggs is now being offered in Toronto but nowhere else in North America. A trial in the US was voluntarily suspended after the Food and Drug Administration suggested the treatment may be considered an “investigational new drug” requiring approval. In Canada, it may fall outside regulation, though Health Canada has not made any formal response to date.

The treatment, called Augment, involves extracting mitochondria, a cell’s energy supply, from a woman’s ovarian stem cells and injecting them into her eggs during in vitro fertilization. In December 2014, OvaScience, the US-based company that developed Augment, announced that the treatment would be offered commercially. No clinical data on efficacy were provided, though the company noted that 150 women had been enrolled in experimental trials at four sites worldwide. These include the Toronto Centre for Advanced Reproductive Technology (TCART) and clinics in London, Istanbul and Dubai. OvaScience Chief Executive Officer Michelle Dipp said they expected Augment would be used in approximately 1000 paying patients in 2015.

Underactive mitochondria are thought to be a key reason why older eggs fail to develop into blastocysts — embryos that are ready to implant. Augment adds extra, and apparently less mutated, mitochondria. The researchers think the additional mitochondria provide the energy needed for successful cell division. Research in pigs has shown that adding mitochondria leads to higher rates of pregnancy. Research in humans also suggested that mitochondria borrowed from young donated eggs increased chances of pregnancy, but the idea of using another woman’s mitochondria raised safety concerns, and a moratorium was placed on the practice more than a decade ago.

Figure

A new treatment boosts the energy in eggs by extracting mitochondria (depicted) from a woman’s ovarian stem cells and injecting them into her eggs during in vitro fertilization.

Image courtesy of Harvard Medical School

Augment gets around that problem by using the would-be mother’s own mitochondria. This only became possible after Jonathan Tilly, a researcher then at Harvard Medical School, discovered that the adult human ovary contained stem cells, capable of giving rise to fully mature oocytes. Though Tilly had previously identified them in mice, it was the discovery in humans that shook things up, overturning the decades-old belief that human females are born with all the eggs they will ever possess. Tilly and colleagues founded OvaScience, which is dedicated to developing fertility treatments based on ovarian stem cells.

Augment requires a woman to undergo an ovarian biopsy, during which pieces of her ovary’s outer layer, where ovarian stem cells reside, are removed. After the stem cells are harvested, they are counted and frozen. On the day of egg retrieval, the stem cells are thawed and the mitochondria are isolated, prepared and then injected into the eggs along with sperm.

The Augment lab in Toronto, located within TCART premises, was built and is operated by OvaScience, whose technicians carry out the proprietary process. Dr. Robert Casper, medical director of TCART and a professor at the University of Toronto, says the clinic has enrolled 60 Canadian patients into the trial, and by the end of 2014, 15 of them had completed their cycles.

“It’s looking promising,” says Casper, who declined to provide specific numbers. “We’re getting blastocysts in people who didn’t get blastocysts before, and we’ve got some pregnancies already. We’re very encouraged.” Casper, who is also a senior investigator at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute, has also carried out extensive research on mitochondria.

Trial participants did not pay for any part of the treatment, says Casper. But he estimates that Augment will add about $25 000 to the cost of an IVF cycle. Most of that cost is set by OvaScience, which charges clinics a fixed fee for each cycle. Many of the Augment patients at TCART in 2015 are expected to be from the US.

In September 2013, OvaScience, based in Boston, voluntarily suspended its US trial after receiving a notice from the FDA. OvaScience had assumed it did not need regulatory approval, since the process involved injecting a woman’s own organelles into her own egg using a method already used to deliver sperm. Neither the FDA nor the company would comment on the status of Augment in the US, but the company has now announced it will be establishing its international headquarters in the UK.

Ubaka Ogbogu, a professor in the faculties of Law and Pharmacy & Pharmaceutical Sciences at the University of Alberta in Edmonton, notes that the FDA and Health Canada differ in their approach to medical treatments.

“Health Canada has taken the position that they don’t regulate treatments,” he says. But he believes that is problematic: “At a minimum, this is an experiment and needs regulatory scrutiny. To regard it as a treatment procedure is dishonest.”

Dr. Arthur Leader, cofounder of the Ottawa Fertility Centre and a former member of the stem cell oversight committee of the Canadian Institutes of Health Research, says his clinic was approached by OvaScience about offering the treatment, but his team declined to pursue it, given the lack of data and regulatory oversight. “We weren’t comfortable with it.”

“I do think there are important questions to ask about the children who result,” says Marcy Darnovsky, executive director of the Center for Genetics and Society, an advocacy group based in Berkeley, California. “I sure would want to see a clinical trial.”

Arthur Caplan, a bioethicist at New York University Langone Medical Center in New York City agrees: “You’re innovating in an area where the burden of a bad outcome goes on for a lifetime and the person bearing the highest cost can’t consent.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (3)
CMAJ
Vol. 187, Issue 3
17 Feb 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
IVF booster offered in Canada but not US
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IVF booster offered in Canada but not US
Alison Motluk
CMAJ Feb 2015, 187 (3) E89-E90; DOI: 10.1503/cmaj.109-4975

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
IVF booster offered in Canada but not US
Alison Motluk
CMAJ Feb 2015, 187 (3) E89-E90; DOI: 10.1503/cmaj.109-4975
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • How Canadian hospitals are decreasing carbon emissions
  • National survey highlights worsening primary care access
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire